Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
about
Vaccines for gonorrhea: can we rise to the challenge?Meningococcal VaccinationsMeningococcal B vaccination strategies and their practical application in ItalyEpidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriageThe Evolution of the Meningitis Vaccine ProjectStructural and Kinetic Characterizations of the Polysialic Acid O-Acetyltransferase OatWY from Neisseria meningitidisMeningococcal carriage and disease--population biology and evolutionAge-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgGEmergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina FasoInfections of People with Complement Deficiencies and Patients Who Have Undergone SplenectomyRecent Progress in the Prevention of Serogroup B Meningococcal Disease.Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.Resolution of a meningococcal disease outbreak from whole-genome sequence data with rapid Web-based analysis methods.Influence of two vaccination campaigns on genetic diversity of invasive Neisseria meningitidis isolates in northern Spain (1997-2008)The influence of IS1301 in the capsule biosynthesis locus on meningococcal carriage and disease.Carriage rate and effects of vaccination after outbreaks of serogroup C meningococcal disease, Brazil, 2010.Review of meningococcal group B vaccines.Epidemiological profile of meningococcal disease in the United StatesClinical and laboratory evidence for Neisseria meningitidis biofilms.Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years.Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in CubaA model-based analysis: what potential could there be for a S. aureus vaccine in a hospital setting on top of other preventative measures?Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagersUpdated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunityGlobal practices of meningococcal vaccine use and impact on invasive disease.Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal serogroup C conjugate vaccine.Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Genetic diversity and levels of expression of factor H binding protein among carriage isolates of Neisseria meningitidis.Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.Neisseria meningitidis: biology, microbiology, and epidemiology.Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.Clonal analysis of meningococci during a 26 year period prior to the introduction of meningococcal serogroup C vaccines.Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics.A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
P2860
Q21131153-8599622F-C8C2-4C61-87E1-7D1834CDF44CQ26752993-9D93B32D-818A-4702-ABC7-D69FABA00055Q26770699-951C4336-23FD-437E-AED9-7222C8279079Q26770707-23C94A30-5D41-4CEE-AF98-65487DF895BBQ26778281-9D075E42-E769-40B7-B31C-BA7AD42C36A8Q27655942-767A0397-F3ED-4E9E-91FF-4915088A0523Q28246008-88C9F0A4-BF1A-44B3-8F5B-B5CD803EDC5DQ28741100-60E5038F-2613-4667-B104-D90A0D97BE48Q28744396-610C423E-0665-4F67-A1F0-193CC6B77ECEQ28972389-4F309952-D5CA-4FC3-B91C-DBC52D65BAEEQ30235040-CE0E3893-1BB2-455A-903E-A15B5BDE6EACQ30239049-1815BEF7-BC90-4A16-8203-CEC24456B194Q30431534-6BA0D580-2A63-4E51-9687-EB2C09F8F595Q30464193-97F3E75D-E43D-43BD-B1F8-B64CC3609009Q33521231-F8AB2F25-A6C5-4233-BDEC-9F68FA78F607Q33535924-805A9C84-77B8-47E7-BF16-A6F026C51447Q33577121-94806E0A-1968-47D0-B938-C9D65F7C8145Q33646965-8E712A3E-1D18-467F-9CEF-5067A8F26BE2Q33648635-DDBF4FF7-C9C3-4E46-B369-D4E30AAF56C1Q33685515-E0EE53CC-A825-4038-8F22-31B392DF8D1FQ33703560-18F16A97-5A32-4ED3-89A8-C6EA2CBA3590Q33704817-2E4468DB-8472-4EC0-B15C-80318E8CB8C7Q33714965-6006CD96-F226-4757-B7E3-6BFDF5506F34Q33806774-516BFE8F-CF28-451B-8903-08E4B2A5522EQ33825722-1E97CB63-8358-481E-BFBF-2772671D465CQ33850840-798186A6-9B33-4831-BD52-8DD0A57E75CFQ33962704-47FCE3F0-21DC-4E9B-88DC-EDD782ED62ABQ34153704-549A453A-07A0-4982-928A-74096E64619EQ34155231-708252EA-16DF-4E77-9C1F-C20DDD523BCDQ34170021-571632F6-3C93-4546-87A2-B6647A23B863Q34231871-8088BAC6-4D61-429C-801D-332EA0E1DB7AQ34346578-1CC62A73-7DE0-41DF-A870-97E4A275D0ADQ34627685-256EE5F5-3738-45DF-92C0-8501D46EBB13Q34632986-84F4ADDE-1D6A-4BBA-AE4F-15BFDB871ECAQ34707962-D382F6FE-AC0D-4B33-B39D-16DF32FC2960Q34721179-C82CCE03-5306-4C31-A579-9DE938F76C87Q34738958-EDDA3AD2-3799-4871-9104-09F4F8F28012Q35006862-F6C77EBA-25AC-4E23-8226-5CDEC5B64A6DQ35048994-F9F7DB41-F8B3-4204-B229-23D046AE90E1Q35181636-ED5D3B07-4CA9-4570-BE7F-D990876C62A7
P2860
Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
description
im März 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 March 2008
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2008
@uk
name
Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
@en
Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
@nl
type
label
Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
@en
Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
@nl
prefLabel
Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
@en
Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
@nl
P2093
P2860
P50
P356
P1476
Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity
@en
P2093
A Mark Walker
Ana Belén Ibarz-Pavón
David Baxter
Derrick W Crook
Dlawer A A Ala'aldeen
Edward Kaczmarski
J Claire Cameron
J Simon Kroll
James M Stuart
Jenny Maclennan
P2860
P304
P356
10.1086/527401
P407
P577
2008-03-01T00:00:00Z